OQS Stock Overview
Operates as an infection prevention company globally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nanosonics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.95 |
| 52 Week High | AU$2.78 |
| 52 Week Low | AU$1.56 |
| Beta | 1.56 |
| 11 Month Change | -1.02% |
| 3 Month Change | 0% |
| 1 Year Change | -21.37% |
| 33 Year Change | -41.96% |
| 5 Year Change | -53.35% |
| Change since IPO | 329.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| OQS | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.4% | 0.5% | 0.2% |
| 1Y | -21.4% | -6.8% | 8.5% |
Return vs Industry: OQS underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: OQS underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| OQS volatility | |
|---|---|
| OQS Average Weekly Movement | 8.3% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: OQS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OQS's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 466 | Michael Kavanagh | www.nanosonics.com.au |
Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform.
Nanosonics Limited Fundamentals Summary
| OQS fundamental statistics | |
|---|---|
| Market cap | €605.08m |
| Earnings (TTM) | €8.04m |
| Revenue (TTM) | €105.31m |
75.3x
P/E Ratio5.7x
P/S RatioIs OQS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OQS income statement (TTM) | |
|---|---|
| Revenue | AU$170.01m |
| Cost of Revenue | AU$37.58m |
| Gross Profit | AU$132.44m |
| Other Expenses | AU$119.47m |
| Earnings | AU$12.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.043 |
| Gross Margin | 77.90% |
| Net Profit Margin | 7.63% |
| Debt/Equity Ratio | 0% |
How did OQS perform over the long term?
See historical performance and comparison